Regulation of B Cell Function by Lobenzarit, A Novel Disease-Modifying Antirheumatic Drug

✍ Scribed by Shunsei Hirohata; Satoshi Shinohara; Tetsufumi Inoue; Terumasa Miyamoto; Peter E. Lipsky

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: English
• Weight: 718 KB
• Volume: 35
• Category: Article
• ISSN: 0004-3591
• DOI: 10.1002/art.1780350208

✦ Synopsis

Objective. Lobenzarit (disodium 4-chloro-2,2'iminodibenzoate [CCA]) is a novel disease-modifying drug for the treatment of rheumatoid arthritis (RA). Although its clinical efficacy has been demonstrated, its mechanism of action remains unclear. We therefore examined the effects of CCA on in vitro IgM and IgM rheumatoid factor (IgM-RF) production by human B cells.

Methods. IgM and IgM-RF production was induced from highly purified B cells from 8 healthy donors by stimulation with Stuphylococcus aureus Cowan 1 (SAC) plus factors generated from mitogen-activated T cells (TCF) or with immobilized anti-CDhctivated CD4+ T cells.

Results. CCA suppressed the production of IgM-RF as well as IgM at concentrations of 25-50 &ml (therapeutic serum concentrations of the drug), al-From the Department of Medicine and Physical Therapy,